NCT05727176招募中2 期
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 164
- 主要终点
- ORR by independent central review
研究概览
简要总结
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
详细描述
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements. Eligible patients will be randomized on a 1:1 basis to the following study arms:
- Patients will receive futibatinib at an oral dose of 16 mg, administered daily (QD) on every day of a 21-day cycle.
- Patients will receive futibatinib at an oral dose of 20 mg, administered daily (QD) on every day of a 21-day cycle.
Patients may continue to receive continuous futibatinib until documentation of progressive disease (PD) per RECIST 1.1, or until other withdrawal criteria are met, whichever comes first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed, locally advanced, metastatic, or unresectable intrahepatic of extrahepatic Cholangiocarcinoma.
- •Documented evidence of FGFR2 gene fusions or other FGFR2 rearrangement
- •Received at least one prior systemic gemcitabine and platinum-based regimen for CCA
- •Documentation of radiographic disease progression on the most recent prior therapy
- •Measurable disease
- •performance status 0 or 1
- •Adequate organ function
排除标准
- •History or current evidence of calcium and phosphate homeostasis disorder
- •Current evidence of clinically significant retinal disorder
- •Treatment with any of the following within the specified time frame prior to the first dose of futibatinib:
- •Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of futibatinib) and radiotherapy for extended field within 4 weeks or limited field radiotherapy within 2 weeks
- •Patients with locoregional therapy, eg, transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) or ablation within 4 weeks
- •Any non investigational anticancer therapy within 3 weeks or have not recovered from side effects of such therapy prior to futibatinib. Endocrine therapy is allowed for patients with breast or prostate cancer
- •Targeted therapy or immunotherapy within 3 weeks or within 5 half lives Any investigational agent received within 5 half-lives of the drug or 4 weeks, whichever is shorter.
- •Patients with prior FGFR-directed therapy
- •A serious illness or medical condition(s) including (but not limited to) the following:
- •Known brain metastasis (not including primary brain tumors) unless patient is clinically stable for ≥1 month
- •Known acute systemic infection
- •Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or IV New York Heart Association [NYHA] Classification) within the previous 2 months; if >2 months, cardiac function must be within normal limits and the patient must be free of cardiac-related symptoms
- •Significant gastrointestinal disorder(s) that could interfere with the absorption of futibatinib.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the Investigator would make the patient inappropriate for entry into this study.
- •Known additional malignancy that is progressing or requires active treatment, with the exception of patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or antitumor assessment of the investigational regimen. Exceptions must be discussed with the Sponsor prior to patient enrollment.
- •Pregnant or lactating female.
- •Known hypersensitivity or severe reaction to futibatinib or its excipients.
研究组 & 干预措施
Treatment Arm B
Experimental
TAS-120 (16mg) tablets, oral; 21-day cycle
干预措施: TAS-120 (Drug)
Treatment Arm A
Experimental
TAS-120 (20mg) tablets, oral; 21-day cycle
干预措施: TAS-120 (Drug)
结局指标
主要结局
ORR by independent central review
时间窗: 12 months after the study completion
defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST 1.1), based on ICR
次要结局
- Change from Baseline in Quality of life as assessed by EORTC QLQ-C30(up to 12 months after the study completion)
- DoR by independent review(up to 12 months after the study completion)
- PFS by independent review(up to 12 months after the study completion)
- PFS per Investigator assessment(up to 12 months after the study completion)
- Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0(up to 12 months after the study completion)
- ORR per Investigator assessment(up to 12 months after the study completion)
- OS(up to 12 months after the study completion)
- DoR per Investigator assessment(up to 12 months after the study completion)
- Change from Baseline in Quality of life as assessed by EuroQol-5D (EQ-5D )(up to 12 months after the study completion)
研究者
研究点 (164)
Loading locations...
相似试验
进行中（未招募）
2 期
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerEsophageal AdenocarcinomaEsophageal Squamous Cell CancerSiewert Type 1 GEJ CancerPancreatic CancerNCT05945823Taiho Oncology, Inc.53
Unknown
2 期
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaMyelogenous Leukemia, ChronicNCT01503502Jiangsu HengRui Medicine Co., Ltd.150
已完成
2 期
Ponatinib in Advanced NSCLC w/ RET TranslocationsNon Small Cell Lung CancerNCT01813734Massachusetts General Hospital9
已完成
1 期
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 MutationAcute Myelogenous LeukemiaMyelodysplastic SyndromeAcute Myeloid LeukemiaNCT02719574Forma Therapeutics, Inc.336
已完成
2 期
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate CancerHormone Refractory Prostate CancerNCT01215799CytRx23